{"created":"2023-07-27T06:50:46.458033+00:00","id":43872,"links":{},"metadata":{"_buckets":{"deposit":"c5d1c2e5-06db-4f26-a250-2b2b0e1671f2"},"_deposit":{"created_by":18,"id":"43872","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"43872"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00043872","sets":["2812:2813:2816"]},"author_link":["72419","45522"],"item_9_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-06-28","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"4p.","bibliographicVolumeNumber":"2016-04-01 – 2018-03-31","bibliographic_titles":[{"bibliographic_title":"平成29(2017)年度 科学研究費補助金 若手研究(B) 研究成果報告書"},{"bibliographic_title":"2017 Fiscal Year Final Research Report","bibliographic_titleLang":"en"}]}]},"item_9_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{}],"nameIdentifiers":[{},{},{},{}]}]},"item_9_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"ALKチロシンキナーゼ阻害薬（ALK-TKI)はALK肺癌に著効を示す分子標的薬であり、臨床で使用されている。しかし、1～2年程度で耐性を獲得することが問題となっている。近年、その獲得耐性機構として上皮間葉転換（EMT)が注目されているが、克服治療は確立されていない。本研究により、マウスの耐性腫瘍モデルにおいて薬剤Aは上皮系を誘導することで耐性克服できることが示唆された。また、大規模スクリーニングにより5種類の阻害薬で耐性株のE-カドヘリン発現誘導能を確認した。これらの結果から、miR-200cの発現誘導がALK肺癌のEMTによる耐性克服の戦略として有望であることが強く示唆された。","subitem_description_type":"Abstract"},{"subitem_description":"ALK rearrangement, most commonly EML4-ALK, is detected in approximately 5% of non-small cell lung cancer (NSCLC). While ALK tyrosine kinase inhibitor (TKI) shows dramatic clinical efficacy in ALK-rearranged NSCLC patients, almost all patients acquire resistance over time. Epithelial mesenchymal transition (EMT) was also reported to be associated with various targeted drugs, however, its involvement in ALK-inhibitor resistance is largely unknown. We found that pre-treatment with Drug A can overcome the resistance by reverting EMT, in vitro and in vivo, due to up-regulation of miR-200c. The results of drug screening on a 200 kinase inhibitor library showed that 5 drugs increased E-cadherin expression of the resistant cells. These findings indicate that chemical restoration of miR-200c could be useful to circumvent resistance due to EMT in ALK-rearranged NSCLC.","subitem_description_type":"Abstract"}]},"item_9_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号:16K19447, 研究期間(年度):2016-04-01 – 2018-03-31","subitem_description_type":"Other"},{"subitem_description":"出典：研究課題「ALK肺癌のEMTに起因するALK-TKI耐性克服治療の開発」課題番号16K19447\n（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） \n（https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-16K19447/16K19447seika/）を加工して作成","subitem_description_type":"Other"}]},"item_9_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学がん進展制御研究所","subitem_description_type":"Other"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00050214","subitem_identifier_reg_type":"JaLC"}]},"item_9_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/search/?qm=10722548"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/search/?qm=10722548","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-16K19447/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-16K19447/","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-16K19447/16K19447seika/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-16K19447/16K19447seika/","subitem_relation_type_select":"URI"}}]},"item_9_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-04-06"}],"displaytype":"detail","filename":"CA-PR-FUKUDA-K-kaken 2018-4p.pdf","filesize":[{"value":"432.4 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"CA-PR-FUKUDA-K-kaken 2018-4p.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/43872/files/CA-PR-FUKUDA-K-kaken 2018-4p.pdf"},"version_id":"ccb30575-8b09-43bc-9407-9068b61ed3ad"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"ALK肺癌のEMTに起因するALK-TKI耐性克服治療の開発","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"ALK肺癌のEMTに起因するALK-TKI耐性克服治療の開発"},{"subitem_title":"Development of ALK-TKI-resistant treatment due to EMT of ALK lung cancer","subitem_title_language":"en"}]},"item_type_id":"9","owner":"18","path":["2816"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-04-06"},"publish_date":"2019-04-06","publish_status":"0","recid":"43872","relation_version_is_last":true,"title":["ALK肺癌のEMTに起因するALK-TKI耐性克服治療の開発"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2023-07-27T13:03:27.307284+00:00"}